NasdaqCM - Nasdaq Real Time Price USD

Dogwood Therapeutics, Inc. (DWTX)

Compare

2.3600

-0.0900

(-3.67%)

At close: January 10 at 4:00:00 PM EST

2.4500

+0.09

+(3.81%)

After hours: January 10 at 5:12:45 PM EST

Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study

- IMC-2 treatment, dosed as valacyclovir 750 mg + celecoxib 200 mg twice daily, demonstrated clinically meaningful reduction in Long-COVID related fatigue and sleep disturbance as compared to placebo – - Top-line results from the Bateman Horne Center’s Long-COVID study provide key insights into final design of Dogwood’s planned Phase 2 study, projected to enroll approximately 200 participants - ATLANTA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”),

GlobeNewswire last month

DWTX
-3.67%
DWTX: Phase 2 Long COVID Results Expected Soon

By David Bautz, PhD NASDAQ:DWTX READ THE FULL DWTX RESEARCH REPORT Business Update Phase 2 Long COVID Results Expected Soon Dogwood Therapeutics, Inc. (NASDAQ:DWTX) is advancing IMC-2 (valacyclovir + celecoxib) as a treatment for Long COVID. The drug is currently being evaluated in a Phase 2a clinical trial being conducted by the Bateman Horne Center (BHC). Dogwood previously supplied the BHC

Zacks Small Cap Research last month

DWTX
-3.67%
Q3 2024 Dogwood Therapeutics Inc Earnings Call

Q3 2024 Dogwood Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

DWTX
-3.67%
Dogwood Therapeutics Inc (DWTX) Q3 2024 Earnings Call Highlights: Strategic Financing and ...

Dogwood Therapeutics Inc (DWTX) reports significant advancements in clinical trials and secures strategic financing to bolster its pipeline and future development.

GuruFocus.com 2 months ago

DWTX
-3.67%
Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

- Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) formed in October by combination of Virios Therapeutics, Inc. and Pharmagesic (Holdings) Inc., 100% parent company of Wex Pharmaceuticals, Inc. (the “Combination”) - - Expanded pipeline with multiple programs in large markets with high unmet need - - Strategic financing results in combined working capital of approximately $23 million to fund operations and advance Phase 2b Halneuron® development through 2025 - - Top-line results from Long-COVID Phase

GlobeNewswire 2 months ago

DWTX
-3.67%
Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024

ATLANTA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), formerly Virios Therapeutics, Inc., a clinical‐stage biopharmaceutical company, announced today that it will report third quarter 2024 financial results on Thursday, November 7, 2024 before the open of the financial markets. Management will also host a webcast and conference call on November 7, 2024 at 8:30 a.m. ET to discuss the results and provide a corporate update. The live and archived webc

GlobeNewswire 2 months ago

DWTX
-3.67%
Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

ATLANTA, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), formerly Virios Therapeutics, Inc., a clinical‐stage biopharmaceutical company, announced today that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The listing compliance matter is now closed. Below are some recent key developments in the business. Key Highlights Top-line results from the Bateman Horne Center’s phase 2a study

GlobeNewswire 2 months ago

DWTX
-3.67%
DWTX: Virios Therapeutics Becomes Dogwood Therapeutics; Focus on Chemotherapy-Induced Neuropathic Pain…

By David Bautz, PhD NASDAQ:DWTX READ THE FULL DWTX RESEARCH REPORT Business Update Virios Combines with Wex Pharmaceuticals to Form Dogwood Therapeutics On October 7, 2024, Virios Therapeutics, Inc. (NASDAQ:VIRI) announced a business combination with privately-held Wex Pharmaceuticals, Inc. to form Dogwood Therapeutics, Inc. (NASDAQ:DWTX). The combined company will be focused on the clinical

Zacks Small Cap Research 2 months ago

DWTX
-3.67%

Performance Overview

Return	DWTX	S&P 500
YTD	-17.19%	-1.35%
1-Year	-86.40%	+22.51%
3-Year	-98.32%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Dogwood Therapeutics, Inc. (DWTX)

Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study

DWTX: Phase 2 Long COVID Results Expected Soon

Q3 2024 Dogwood Therapeutics Inc Earnings Call

Dogwood Therapeutics Inc (DWTX) Q3 2024 Earnings Call Highlights: Strategic Financing and ...

Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024

Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

DWTX: Virios Therapeutics Becomes Dogwood Therapeutics; Focus on Chemotherapy-Induced Neuropathic Pain…

Performance Overview